Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). by Hardy J et al.
STUDY PROTOCOL Open Access
Oral medicinal cannabinoids to relieve
symptom burden in the palliative care of
patients with advanced cancer: a double-
blind, placebo-controlled, randomised
clinical trial of efficacy and safety of 1:1
delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD)
Janet Hardy1, Alison Haywood2,3, Gauri Gogna4, Jennifer Martin5,6, Patsy Yates7,8, Ristan Greer3 and Phillip Good9*
Abstract
Background: Despite improvements in medical care, patients with advanced cancer still experience substantial
symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence
to guide clinicians. This study aims to define the role of a 1:1 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD)
cannabinoid preparation in the management of symptom burden in patients with advanced cancer undergoing
standard palliative care.
Methods and design: One hundred fifty participants will be recruited from five sites within the Queensland
Palliative Care Research Group (QPCRG) and randomly assigned to an active treatment or placebo group. This study
is a pragmatic multicentre, randomised, placebo-controlled, two-arm trial of escalating doses of an oral 1:1 THC/
CBD cannabinoid preparation. It will compare efficacy and safety outcomes of a titrated dose (10 mg/10 mg/mL oral
solution formulation, dose range 2.5 mg/2.5 mg–30 mg/30 mg/day) against placebo. There is a 2-week patient-
determined titration phase, using escalating doses of 1:1 THC/CBD or placebo, to reach a dose that achieves
symptom relief with tolerable side effects. This is then followed by a further 2-week assessment period on the
stable dose determined in collaboration with clinicians. The primary objective is to assess the effect of escalating
doses of a 1:1 THC/CBD cannabinoid preparation against placebo on change in total symptom score, with
secondary objectives including establishing a patient-determined effective dose, the change in total physical and
emotional sores, global impression of change, anxiety and depression, opioid use, quality of life and adverse effects.
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Discussion: This will be the first placebo-controlled clinical trial to rigorously evaluate the efficacy, safety and
acceptability of 1:1 THC/CBD for symptom relief in advanced cancer patients. This study will allow the medical
community to have some evidence to present to patients wishing to access cannabis for their symptoms caused
by advanced malignancy.
Trial registration: ACTRN, ACTRN12619000037101. Registered on 14 January 2019.
Trial Sponsor: Mater Misericordiae Limited (MML) and Mater Medical Research Institute Limited (MMRI)—Raymond
Terrace, South Brisbane, Brisbane, QLD, Australia
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Background
Despite improvements in medical care, patients with ad-
vanced cancer still experience substantial symptom distress
[1]. Palliative care aims to take a skilled, holistic approach
to improve patients’ symptoms and quality of life. Whilst
there is a range of analgesic medication available for pain
management, the control of many other symptoms (e.g. fa-
tigue, anorexia, weight loss) remains a challenge [2].
There has been increasing interest in the use of medi-
cinal cannabinoids over recent years, particularly for the
relief of symptoms in palliative care patients [3]. Recent
legislative change in several Australian states provided
pathways for the use of medicinal cannabinoids for a
range of indications including chemotherapy-induced
nausea and vomiting (CINV), resistant epilepsy, pain and
spasticity in multiple sclerosis, and symptoms associated
with terminal illness [4].
Cannabis contains almost 500 bioactive compounds, in-
cluding over 70 different cannabinoids [5]. The predomin-
ant cannabinoids include delta-9-tetrahydrocannabinol
(THC) and cannabidiol (CBD). THC is the main psycho-
active component of cannabinoids and is thought to act as
a partial agonist on the endocannabinoid system. Potential
benefits of THC include analgesia, anti-nausea and muscle
relaxation, with potential side effects including intoxica-
tion, psychosis, anxiety and sedation. The recommended
dose range for oral THC varies from 2.5 to 40mg/day [6].
In contrast, CBD is not intoxicating and has a range of
anxiolytic, antipsychotic, anti-inflammatory, anti-
oxidative, anti-convulsant and neuroprotective effects [7].
CBD is also considered to mediate many of the adverse
psychotropic effects of THC, although this research is still
emerging [8]. CBD has been used with a dosing in the
range of 40 to 1280mg/day orally [9].
There is little high-quality evidence of benefit to date for
the use of medicinal cannabinoids. The most recent re-
view from the USA National Academies of Sciences, En-
gineering, and Medicine found substantial evidence for
the use of medicinal cannabinoids for treatment of some
types of chronic pain, CINV and spasticity in multiple
sclerosis in some patients, with moderate evidence for
sleep disorders [10]. Cannabinoid products are licenced
for a range of conditions in different countries, with little
consistency between countries for indication and dosing
[11]. Whilst cannabinoids may have clinical indication,
their use is not without potential for substantial harms,
and further research is needed to define their role in med-
ical practice [3, 11].
There are many unknowns when it comes to prescrib-
ing medicinal cannabis [11]. This includes the formula-
tion of the drug (ratios of THC or CBD), the dosing of
the drug and the best route of delivery. Ongoing con-
cerns remain around the uncertainty over the optimal
formulation, toxicity and abuse potential. The 1:1 THC/
CBD ratio used in formulations may deliver sufficient
CBD to ameliorate the psychotoxic effects of THC but is
unlikely to produce significant CBD therapeutic effects.
To date, there has been no formal examination of the
effect of different THC/CBD ratios. We will therefore
compare efficacy and safety outcomes of a 1:1 THC/
CBD formulation against placebo, with doses of both




This study aims to define the role of cannabinoids in the
management of symptoms in patients with advanced
cancer, who are receiving standard palliative care. The
hypothesis is that medicinal cannabinoids will reduce
the total symptom burden in these patients compared to
placebo.
The primary objective is to assess the effect of escalat-
ing doses of a 1:1 THC/CBD cannabinoid preparation
against placebo on total symptom score at day 14 as
measured by the Edmonton Symptom Assessment Scale
(ESAS) (change in score from baseline). Secondary ob-
jectives are to establish a patient-determined effective
dose of a 1:1 THC/CBD formulation and assess the ef-
fect on symptom scores at days 7, 21 and 28. Other sec-
ondary objectives include assessing the change in total
physical and emotional sores, global impression of
change, anxiety and depression, opioid use and quality
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of life at the same time points and to document adverse
effects associated with cannabinoid use.
Study design
This study is a pragmatic multicentre, randomised,
placebo-controlled, two-arm parallel trial of escalating
doses of oral THC/CBD 10mg/10 mg/mL oral solution.
There is a 2-week patient-determined titration phase,
using escalating doses of a 1:1 THC/CBD combination
or placebo, to reach a dose that achieves symptom relief
with tolerable side effects. This is followed by a further
2-week assessment period on the stable dose determined
in collaboration with clinicians.
Eligible patients will be randomly assigned in equal
numbers to one of the two study arms. Randomisation
schedules will be developed for each site using random
number tables, computer generated at an independent
centre. Treatment for each patient will be allocated ac-
cording to a permuted block randomisation schedule held
by the central registry. Block randomisation within each
centre will ensure even allocation to each arm in each site.
The pharmacy will be notified of a participant, and a com-
pleted script with the participant’s study ID number will
be given to the site pharmacy. The pharmacist will ran-
domise the participant according to the schedule and dis-
pense the medication in a labelled bottle. The participant
ID, allocation number, date of request, preparation and
dispensing will be recorded in a log maintained by the site
pharmacist for each randomisation.
All participants, caregivers, investigators and clinical
staff will remain blind to study assignment until trial
completion. The code will only be broken in cases of a
clinical emergency. An investigator not directly involved
in the randomisation of patients will keep an un-blinded
copy of the randomisation schedule and will be con-
tacted in the event of the need to un-blind. All study
drugs and placebo will be in oil solution form and iden-
tical in appearance. All oil solutions will be matched for
taste, colour and bottle size to preserve the blinding irre-
spective of the contents; each participant will receive the
oil solution in a prepacked bottle labelled with their in-
dividual trial participation ID number and consecutively
numbered according to the randomisation scale.
Intervention
Cannabinoid oils, supplied by LG Pharma, will be used
in this study. The decision to use oils was based on a
number of factors including product availability, ability
to access ongoing supplies, ability to produce matched
placebo, regulations surrounding the production and
transport of cannabinoid products and cost.
Arm 1 of the trial consists of THC/CBD 10mg/10mg/
mL oral solution (LG Pharma Pty Ltd) with a dose range
of 2.5 mg/2.5mg–30mg/30mg/day and arm 2 a matching
placebo oral oil solution. Participants are asked to take
daily doses as per dosing schedule instructions. The study
drug is to commence on the day of baseline assessment,
continuing for a maximum of 28 days.
The cannabinoid oils and placebo will be dispensed in
identical 50-mL bottles containing a sufficient quantity
of oil. Bottles are to be stored at room temperature
(25 °C) until used and stored away from light. The prod-
uct will be dispensed from bottles with a wadded child-
resistant cap. Participants will be given replacement bot-
tles to complete the study as required. Participants will
be educated on how to administer daily doses using sup-
plied 1-mL syringes appropriate for the dose. The par-
ticipant will complete a daily dosing schedule diary at
home to record medication taken. Cannabinoid oil that
has been allocated to a participant and not used will be
returned to the research nurse/research officer and
destroyed by the local pharmacy as per pharmacy
guidelines.
Dose titration will be confirmed following regular con-
sultation. Each participant will be advised to increase
their dose according to a schedule every 2 days until
they are satisfied with their symptom improvement or
they experience unacceptable side effects. Dose titration
downwards will also be allowed, in consultation with re-
search staff. The participant in collaboration with re-
search staff will define the dose level at which they will
continue until the primary outcome point (14 days). Par-
ticipants will then be given the option of remaining on
the blinded oil solution for a further 2 weeks (28 days
total) for continuing assessment of efficacy and adverse
events (continue final dose if perceived to be of benefit
and tolerated). Assessment at 28 days following 14 days
of stable dose is a secondary end point.
Study setting
Participants will be recruited from five sites within the
Queensland Palliative Care Research Group (QPCRG).
These five sites have been chosen from the QPCRG as
they have an established research team including research
support systems within Palliative Care and have previous
experience in trial participation in this setting. It is antici-
pated that this will be predominately an outpatient study,
with these sites having the ability to access this participant
population from their established clinic service.
All participants will be given standard palliative care ac-
cording to the local practice of the recruiting centre [12].
They will continue all current medications including opioids,
antiemetics, sedatives and specific anti-cancer therapy (in-
cluding chemotherapy, immunotherapy and radiotherapy).
Study participants
Patients who meet the inclusion criteria will have an ad-
vanced histologically proven cancer diagnosis (metastatic
Hardy et al. Trials          (2020) 21:611 Page 3 of 8
or locally advanced), be known to and be receiving pal-
liative care at the recruiting centre and have an ESAS
Total Symptom Distress Score (TSDS) of ≥ 10/90 for
cancer-related symptoms and at least one individual
ESAS score ≥ 3/10 [13]. They must have a Performance
Status AKPS (Australia-modified Karnofsky Scale score)
of ≥ 30/100 [14], be aged ≥ 25 years, have a negative
THC urine test at commencement of trial and be able to
tolerate oral medications and must be either English-
speaking or have an interpreter available.
Female participants must have a negative pregnancy
urine test at eligibility (only if of reproductive potential)
and agree to avoid pregnancy during the study and 12
weeks following the last dose of the study drug. Males
must agree to avoid fathering a child and to not donate
sperm during the study and for at least 12 weeks follow-
ing the last dose of the study drug. Further to this, the
Alcohol, Smoking and Substance Involvement Screening
Test (ASSIST) will be completed [15]. It is designed to
determine whether harmful substances are being used
and go undetected or become worse. The assessment is
comprised of 8 questions assessing, tobacco, alcohol, co-
caine, amphetamine-type stimulants, sedatives, halluci-
nogens, opiates and ‘other drugs’.
Exclusion criteria include a history of hypersensitivity
to any cannabinoid, unstable untreated cardiovascular
disease, severe hepatic impairment (total bilirubin ≥ 1.5
times the upper limit of the normal range), aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) ≥ 3.0 times the upper limit of the normal range
(subjects with liver metastasis may have an AST and
ALT of ≥ 5.0 times the upper limit of normal), severe
renal impairment (eGFR ≤ 20mL/min/1.73 m2), a history
of psychiatric disorders (severe depression or anxiety,
personality disorder, psychosis, schizophrenia, first-
degree relative with schizophrenia and/or suicidal idea-
tion), cognitive impairment (St Louis University Mental
Status examination (SLUMS) ≤ 20/30) [16] and a known
substance use disorder (Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST) examination scor-
ing > 27) for any substance.
Potential participants will be excluded if they have a
history suggesting that drug diversion may be a risk for
them or their family/carers, have participated in a trial
of a new clinical entity within the last 28 days or had
treatment with a new specific anti-cancer agent (chemo-
therapy, targeted or hormonal therapy) or radiation
within the last 7 days.
Consent process
The process for obtaining consent for this study will be
exchanging information between the study staff and po-
tential participants and any other person the participant
wishes to include in the discussion. A participant
information sheet (PICF) will be provided in written
form and will be used as the basis for the discussion.
This will cover the purpose, expected procedures, par-
ticipant requirements, risks, benefits, burdens and side
effects that are expected or possible during the study.
Participants are specifically informed that due to the na-
ture of this medication and current laws in Queensland,
you will NOT be able to drive or operate heavy machin-
ery whilst taking the medication. Potential participants
will be given the opportunity (in time and physical cap-
acity) to consider the study and formulate any questions.
All questions will be addressed and answered fully. An
actual time point for consent will not be specified as this
will be determined by the person’s physical condition.
The consent form is to be completed by trained study
team members in accordance with the requirements of
the approving ethics committee. The form is to be
signed and dated by the participant.
Assessments
Participants will receive 2 times/weekly research nurse
phone calls in the first 2 weeks and outpatient clinic
medical review visits at days 7, 14, 21 and 28, with out-
come measures recorded at these points.
Symptom burden will be measured using the Edmon-
ton Symptom Assessment Scale (ESAS). Confirmed doc-
umented disease status will be assessed at days 14 and
28, where applicable.
A routine haematology and biochemistry screen in-
cluding liver function tests will be taken at eligibility/
baseline assessment. Blood for C-reactive protein (CRP)
as a basic test of inflammation will be taken at baseline,
day 14 and day 28. All consenting participants will have
a urine test to confirm nil recent use of THC-related
products as a pre-screen. Female participants of child-
bearing potential will have a urine test to determine
pregnancy. At day 14, a urine sample will be collected
and stored (frozen) until the completion and un-
blinding of the study. Samples will be stored on site and
transported to central storage in batches over the course
of the study. These samples will be for post-trial analysis
for evidence of no THC product use during the trial.
Participants will be contacted at day 56 (+ 4 weeks post
last dose) for the purposes of safety follow-up and re-
cording of post-study cannabinoid use. Date of death
will be recorded for all participants up to the census
point. This protocol has been written in accordance with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) (Table 1).
Outcomes and assessment tools
The primary outcome is the change from baseline of
total ESAS TSDS at day 14.
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The ESAS is a 9-item inventory rated on an 11-point
scale anchored at 0 (no problem) to 10 (worst problem). It
assesses both physical and psychological symptoms, plus
general wellbeing. It has been validated in the assessment
of symptoms in cancer patients [13].
Secondary outcomes include:
1. Patient-determined effective dose of THC/CBD
formulation, defined as the dose that achieves
symptom relief with acceptable side effects.
2. ESAS TSDS at days 7, 21 and 28.
3. Physical and emotional ESAS scores at each time
point.
 Physical scores will be measured by the
Australia-modified Karnofsky Performance Sta-
tus (AKPS) and Resource Utilisation Groups-
Activities of Daily Living Scale (RUG-ADL).
The AKPS is a validated variant of the Kar-
nofsky Performance Status. The Australian
version can be applied to both in- and outpa-
tients and is sensitive to changes in function
over time [14]. The RUG-ADL is an instru-
ment developed for the measurement of nurs-
ing dependency. The ADL scale measures
patients’ needs for assistance in activities of
daily living (eating, bed mobility, transferring
and toileting) [17].
4. Individual symptom scores (descriptive analysis
only).
5. Oral morphine equivalent (OME), average use at
baseline and weekly.
6. Patient Global Impression of Change (PGIC), days
7, 14, 21 and 28.
 This is a subjective measure of symptom change
completed by the patients themselves [18].
7. Clinical Global Impressions (CGI) Scale, days 7, 14,
21 and 28.
 This is a subjective measure of symptom change
completed by the investigating clinician [18].
8. The Depression, Anxiety, Stress Scale (DASS-21)
score baseline and days 14 and 28.
 DASS-21 is a self-reported 21-item scale, 7 ques-
tions per sub-item questionnaire measuring de-
pression, anxiety and stress. The DASS-21 will
be used for assessment at baseline (day 0) and
days 14 and 28 [19].
9. EORTC score QoL baseline and days 14 and 28
[20].
This is a QoL measure found valid for use in a wide
variety of cancer populations. To reduce patient
Table 1 SPIRIT figure—study schedule
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burden, we will use the 15-question subset com-
monly used for the palliative care population.
10. NCI common terminology for adverse events
V4.03, days 2, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25 and
28 [21]
 The NCI CTCAE is a severity grading system for
adverse events. Adverse events relate to an
unfavourable or unintended sign, symptom or
disease temporarily associated with a medical
treatment or a procedure which may not be
related to the medical treatment or procedure.
The CTCAE has a grading of 1 (mild) to 5
(death). The known common adverse events
associated with cannabinoids are confusion,
somnolence, paranoia, anxiety, mood changes,
psychosis, hypertension, tachycardia,
hyperhidrosis, nausea, vomiting and abdominal
pain [21].
The study will assess adverse events (AE) and serious
adverse events (SAE) using the criteria of the NCI
CTCAE V4.0 [21]. The known common AEs associated
with THC/CBD will be specifically addressed at each
time point. Finally, a detailed concurrent medication list
is to be updated and recorded at baseline (day 0) and
days 7, 14, 21 and 28. This is to include over-the-
counter medications, prescribed medications and com-
plementary medication.
Statistical analysis and sample size
Allowing 20% for attrition, and with improvement of ≥ 6
for arm 1 compared to placebo, it is anticipated that 150
participants (75 per arm) should be randomised to achieve
a sample size of 60 participants per arm, assuming 80%
power, a 1:1 randomisation scheme and a type 1 error of
5% (two-tailed), and a standard deviation of 11.6. The
sample size is based on previous work by Hui et al. [13]
who determined the minimal clinically important differ-
ence in the TSDS to be 5.7 [13]. As such, we have elected
to use an improvement of the TSDS of ≥ 6 as a clinically
significant change. Stata software (StataCorp. 2013. Stata
Statistical Software: Release 13. College Station, TX: Stata-
Corp) was used to estimate the sample size.
The superiority of arm 1 compared to placebo will be
tested by comparing the response to each arm after 14
days, relative to baseline.
Descriptive analyses and frequency distributions will
be generated from participants’ demographic and clinical
characteristics, with all variables explored using graph-
ical methods and summary statistics. For the primary
outcome, generalised estimating equations with the ap-
propriate link function will be developed to assess the ef-
fect of treatment adjusted for centre. For secondary
outcomes, where measurements from individual subjects
are recorded several times over the course of the study,
change over time in the various secondary outcome
measures will be assessed using mixed models, account-
ing for within-subject correlation and effects due to
centre. For all statistical analyses, any influence of poten-
tial covariates, for example age, sex, type of cancer and
disease severity, will be explored. This study is powered
to detect superiority of arm 1 over placebo.
An interim analysis will be performed after 50%
participants have completed 14 days of the trial. The
analysis will be performed by an independent biostat-
istician blinded for the treatment allocation and re-
ported to the investigators and the Data Safety
Monitoring Board (DSMB). The purpose of the in-
terim analysis is primarily to monitor and ensure
safety of participants rather than evidence of such
benefit that early stopping of the trial is justified. AEs
and SAEs will be stratified by type and severity. The
frequency of AEs and SAEs will be compared between
treatment groups using chi-square tests and logistic
regression if indicated to adjust for any baseline dif-
ferences between groups. Differences in baseline char-
acteristics are not anticipated, as the randomisation
process should ensure that the patient groups are
similar at baseline. However, as the numbers at in-
terim analysis will be relatively smaller, it is possible
that differences may arise by chance. All baseline
characteristics will be assessed and any imbalance ad-
dressed in the analysis.
If the interim analysis shows a significant difference,
the investigators and DSMB will be un-blinded to the
study groups and make any stopping decision on the
basis of the nature of any AEs and/or SAEs and ethical
grounds, as well as consideration of any statistical differ-
ences between the groups. Grounds for stopping on evi-
dence of clear benefit will be considered. The Peto
approach will be taken with symmetric stopping bound-
aries at p = 0.001.
A detailed statistical analysis plan will be prepared
and ratified by the DSMB. Stata, SAS (SAS® version
9.4 software (SAS Institute Inc., Cary, NC, USA)) or
R (R Core Team (2017). R: A language and environ-
ment for statistical computing. R Foundation for Stat-
istical Computing, Vienna, Austria. URL https://www.
R-project.org/) will be used for analysis and all code
recorded for the purposes of ensuring reproducible
research.
Data collection and management
Data will be sourced from a number of modes. The
study is mainly based in the outpatient clinic, so most
data will be collected from the participant and recoded
in the corresponding CRF or questionnaires. Some data
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will be collected from medical records, but the majority
of the data will be collected from:
Measure Source Collected by
General medical information Clinical record Medical officer
General demographic data Clinical record Study nurse
Pathology results—blood Pathology report Pathology
Pathology results—urine Clinical record Study nurse
Vital signs CRF/clinical record Study nurse
Concurrent
medications/OME










CRF Patient, study nurse,
medical officer
Side effects—safety CRF, clinical record Study nurse, medical
officer
All data collected will be kept in a patient file
(identified by ID number only). All data will be stored in
a locked filing cabinet. At completion of the study, all
CRFs will be collated and archived. Electronic files will
be password protected and held within a locked office.
All patient files will be reconciled and stored along with
all study materials, both hard copy and electronic,
consistent with the regulations of the hospital regarding
the retention and disposal of patient records.
The trial will be conducted with permission and in
accordance with Queensland Health regulations on the
use of medical cannabis and subject to approval and
monitoring by each clinical site’s HREC [4, 22]. An
independent DSMB to include a statistician, clinical
pharmacologist, palliative care specialist and consumers
will be formed and will meet regularly, with primary
responsibility for monitoring adverse and serious
adverse events. All AE’s and SAE’s will be reviewed at a
minimum of 6 monthly intervals, or more frequently if
needed.
Post-trial care
There is no anticipated harm or compensation for trial
participation. Participants may be able to access ongoing
cannabinoid products through entry into other open-
label studies but this is not guaranteed. All clinical inves-
tigators will be approved authorised cannabis prescribers
and will be able to continue to prescribe, as long as the
participant can fund their own supply. Participants will
be informed of approved products and suppliers. The
dose and formulation used post study will be at the dis-
cretion of the patient and prescriber.
Discussion
The use of cannabis for symptom control continues to
be a topical issue within medicine, and this study is the
first placebo-controlled, randomised trial to assess the
efficacy of cannabinoids in advanced cancer patients. A
major strength of this study is that it will target symp-
tom burden as a whole, rather than just individual symp-
toms, in an attempt to capture the improvement in
general wellbeing reported anecdotally by many who
have used cannabis [23, 24]. Randomisation with placebo
is essential because of the well-documented overreport-
ing of benefit in uncontrolled trials and high placebo re-
sponse rates in cancer pain trials [25, 26]. The trial
design is pragmatic, intended to allow as wide a range of
participants as possible, to enable the results to be as
real-world as possible. This study also allows for some
data on dosing and formulation of THC/CBD
specifically.
Trial status
Trial recruitment started on 09 September 2019 with
protocol version number 1.3 (protocol date 30 August
2019). Recruitment is expected to continue until the end
of 2021.
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